4baseCare Raises $10 Million in Series B First Close to Scale AI-Driven Precision Oncology

Bengaluru-based 4baseCare, a precision oncology company focused on building population-relevant clinico-genomic intelligence, has announced the first close of its Series B funding round, raising $10 Million. The round was co-led by prominent investors Ashish Kacholia and Lashit Sanghvi, with participation from existing backer Yali Capital.

The fresh capital marks a significant milestone for 4baseCare, accelerating its mission to make precision cancer care more inclusive and accessible across emerging and underrepresented markets.

Fueling Global Expansion in Precision Oncology

Funds from the Series B first close will be deployed to expand 4baseCare’s hospital-linked genomics laboratory network across India, the Middle East, Southeast Asia, Latin America, and Central Asia. By embedding advanced genomic diagnostics within clinical settings, the company aims to bring world-class precision oncology closer to patients who traditionally lack access to such care.

4baseCare previously raised $5 Million in Series A funding, led by Yali Capital with participation from Infosys, which helped establish its foundational genomics infrastructure and clinician partnerships.

Scaling OncoTwin, Its AI-Powered Oncology Platform

A significant portion of the new funding will also be directed toward scaling OncoTwin, 4baseCare’s AI-driven precision oncology platform. OncoTwin integrates real-world clinico-genomic data with treatment outcomes to provide clinical decision support for oncologists, enabling faster and more confident therapy selection.

The platform’s growing global relevance was underscored recently when OncoTwin was selected for the MSK iHub program at Memorial Sloan Kettering Cancer Center in New York, one of the world’s leading cancer research institutions.

Through products such as OncoTwin Insights, 4baseCare aims to bridge the gap between complex genomic data and real-world clinical decision-making, especially in regions where population-specific cancer data remains limited.

Strong Investor Confidence in Data-Driven Cancer Care

Commenting on the investment, Ashish Kacholia and Lashit Sanghvi, co-leads of the round, said that 4baseCare is building a powerful genomics and AI-driven clinical intelligence platform for inclusive precision oncology. They highlighted the company’s strong hospital partnerships and its ability to deliver high-quality diagnostics directly within clinical workflows, positioning it well for expansion across emerging markets.

Closing the Genomics Data Diversity Gap

According to Hitesh Goswami, CEO of 4baseCare, the funding will enable the company to scale globally while continuing to evolve OncoTwin as a learning system powered by real-world outcomes. “Our goal is to support oncologists with actionable insights that reflect the genetic diversity of global populations, not just Western datasets,” he said.

Founded with a mission to close the data diversity gap in genomics, 4baseCare combines population-relevant genomic testing, AI-driven analytics, and outcomes-linked intelligence to help clinicians deliver more personalized cancer treatment.

As precision medicine gains momentum worldwide, 4baseCare’s latest funding underscores growing investor confidence in AI-powered platforms that promise to reshape the future of oncology care.